Oxford, UK, 22nd February 2011: PharmaDeals® research has revealed that the early stages of recovery are now evident within pharmaceutical deal making activity. The overall number of deals in 2010 grew relative to 2009, and whilst collaborative R&D deals continue to decline in numbers and value, licensing activity is on the increase.

Fintan Walton, PhD, Chief Executive of PharmaVentures says, "The current deal making landscape in the life science industry is fascinating, and reflects the forces for change operating worldwide. For example, research based on our PharmaDeals database shows that deal structures for M&A transactions are becoming more and more complex, yet values are declining. In order to benefit, small and large companies alike will require increasing levels of sophistication in terms of their deal-making ability." The results were recently presented by Dr Walton at the Sachs 4th Annual European Life Sciences CEO Forum for Partnering & Investing held in Zurich, and through analysis published by the journal PharmaDeals Review.

Anne Vindenes Allen, Executive Director for PharmaDeals, explains, "It is vital for industry deal makers to keep pace with these developments and use best available business intelligence. Analysis of our PharmaDeals data shows the variation in values within different deals types, as well as within development stages and therapy areas. We always go the extra mile to source and classify critical information to help our clients distil critical intelligence."

Fintan Walton concludes, "Our consultants help bring companies together to further their mutual aims - it's all about teasing out the win-win scenarios. Without an appreciation for what others are doing in the industry, that is pretty much an impossible task".

Secure a copy of the PharmaDeals Review article, entitled
'Deal Making in 2010' here:pharmadeals.net/download_deal_making_2010

Journal available at pharmadealsreview.com

Information about PharmaDeals v4 Agreements is available atpharmadeals.net/agreements or contact us today.

For further information:

Anne Vindenes Allen
Executive Director, PharmaDeals
+44 (0) 1865 332700
anne.allen@pharmaventures.com

 

- ends -